M. Azizi

I. Meredith, J. Ormiston, U. Hoppe, 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Using social media to recruit study participants for a randomized trial for hypertension

A. Kirtane, Yale Wang, A. Pathak, 2020, European heart journal. Digital health.

Using social media to recruit study participants for a randomised trial for hypertension (Preprint)

A. Kirtane, Yale Wang, A. Pathak, 2020 .

Influence of the M235T polymorphism of human angiotensinogen (AGT) on plasma AGT and renin concentrations after ethinylestradiol administration.

J. Ménard, X. Jeunemaître, M. Azizi, 2000, The Journal of clinical endocrinology and metabolism.

Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing.

K. Khunti, Pankaj Gupta, M. Burnier, 2021, Hypertension.

Urine N-acetyl-Ser-Asp-Lys-Pro measurement as a versatile biomarker to assess adherence to angiotensin-converting enzyme inhibitors

P. Boutouyrie, M. Azizi, A. Blanchard, 2021, Journal of hypertension.

Is there any Hope for Monitoring Adherence in an Efficient and Feasible Way for Resistant Hypertension Diagnosis and Follow-Up?

P. Boutouyrie, M. Azizi, E. Billaud, 2020, Current Hypertension Reports.

Drug Adherence in Resistant Hypertension

S. Laurent, M. Azizi, V. Jullien, 2018 .

Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges

J. Staessen, S. Kjeldsen, M. Azizi, 2016, Current Hypertension Reports.

True antihypertensive efficacy of sequential nephron blockade in patients with resistant hypertension and confirmed medication adherence

S. Laurent, P. Boutouyrie, G. Bobrie, 2013, Journal of hypertension.

The benefit of STent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal artery. The STAR-study: rationale and study design.

J. V. van Engelshoven, W. Mali, P. D. de Leeuw, 2003, Journal of nephrology.

Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli.

H. Vaudry, P. Corvol, N. Chartrel, 2008, Journal of the American Society of Nephrology : JASN.

Resistant Hypertension and Atherosclerotic Renal Artery Stenosis: Effects of Angioplasty on Ambulatory Blood Pressure. A Retrospective Uncontrolled Single-Center Study.

É. Mousseaux, G. Bobrie, L. Amar, 2019, Hypertension.

European consensus on the diagnosis and management of fibromuscular dysplasia.

P. D. de Leeuw, X. Jeunemaître, A. Morganti, 2014, Journal of hypertension.

Results Arhgef 1 Is Required for Ang II – Mediated RhoA-Rho Kinase Activation in HCASMC

X. Jeunemaître, P. Pacaud, M. Azizi, 2022 .

Partial genetic deficiency in tissue kallikrein impairs adaptation to high potassium intake in humans.

X. Jeunemaître, R. Chambrey, M. Azizi, 2013, Kidney international.

Expert consensus: Renal denervation for the treatment of hypertension.

H. Benamer, A. Pathak, X. Girerd, 2012, Diagnostic and Interventional Imaging.

Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium

P. Whelton, G. Stone, G. Parati, 2022, Circulation.

Renal denervation in hypertension: Towards a true revival?

M. Azizi, P. Lantelme, P. Courand, 2018, Archives of cardiovascular diseases.

A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs.

K. Kario, A. Kirtane, R. Schmieder, 2018, American heart journal.

European Society of Hypertension position paper on renal denervation 2018.

G. Mancia, C. Tsioufis, R. Schmieder, 2018, Journal of hypertension.

Twenty-Four-Hour Blood Pressure Monitoring to Predict and Assess Impact of Renal Denervation: The DENERHTN Study (Renal Denervation for Hypertension)

A. Cremer, P. Gosse, G. Chatellier, 2017, Hypertension.

Twenty-Four-Hour Blood Pressure Monitoring to Predict and Assess Impact of Renal Denervation

A. Cremer, P. Gosse, G. Chatellier, 2017 .

Design of renal denervation studies not confounded by antihypertensive drugs.

S. Kjeldsen, M. Azizi, A. Persu, 2015, Journal of the American Society of Hypertension : JASH.

Hyperresponders vs. nonresponder patients after renal denervation: do they differ?

J. Staessen, M. Burnier, S. Kjeldsen, 2014, Journal of hypertension.

Residual effect of renal denervation in patients with truly resistant hypertension.

J. Staessen, M. Burnier, M. Azizi, 2013, Hypertension.

Expert consensus: renal denervation for the treatment of arterial hypertension.

H. Benamer, A. Pathak, X. Girerd, 2012, Archives of cardiovascular diseases.

ECOMMENDATIONS / Technical xpert consensus : Renal denervation for the reatment of hypertension

M. Azizi, Hakim Benamerd, Jean-Michel Halimie, 2012 .

Renal denervation and treatment-resistant hypertension: a matter of importance for interventional radiology.

M. Azizi, M. Sapoval, 2012, Diagnostic and interventional imaging.

Eligibility for renal denervation in patients with resistant hypertension: when enthusiasm meets reality in real-life patients.

G. Bobrie, P. Plouin, S. Savard, 2012, Journal of the American College of Cardiology.

Endovascular Renal Artery Denervation: Why, When, and How?

B. Cholley, G. Bobrie, P. Plouin, 2012, CardioVascular and Interventional Radiology.

Genetic deficiency in tissue kallikrein activity in mouse and man: effect on arteries, heart and kidney

P. Meneton, N. Picard, M. Azizi, 2008, Biological chemistry.

Functional consequences of angiotensin-converting enzyme gene polymorphism on N-acetyl-Ser-Asp-Lys-Pro degradation and angiotensin II production

J. Ménard, C. Junot, E. Ezan, 2002, Journal of Molecular Medicine.

Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects.

J. Ménard, M. Azizi, F. Alhenc-Gelas, 1995, Circulation.

Combined Blockade of the Renin Angiotensin System with ACE Inhibitors and AT1 Receptor Antagonists

J. Ménard, M. Azizi, 2004 .

Angiotensin I‐Converting Enzyme And Metabolism Of The Haematological Peptide N‐Acetyl‐Seryl‐Aspartyl‐Lysyl‐Proline

J. Ménard, C. Junot, E. Ezan, 2001, Clinical and experimental pharmacology & physiology.

Vasopeptidase Inhibitor In Vitro and In Vivo Inhibition of the 2 Active Sites of ACE by Omapatrilat , a

P. Corvol, M. Azizi, A. Michaud, 2000 .

In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor.

P. Corvol, M. Azizi, A. Michaud, 2000, Hypertension.

Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in rats.

J. Ménard, C. Junot, E. Ezan, 1999, The Journal of pharmacology and experimental therapeutics.

Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans.

J. Ménard, J. Wdzieczak‐Bakala, E. Ezan, 1999, Hypertension.

High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition.

J. Ménard, E. Ezan, M. Azizi, 1997, Hypertension.

Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.

J. Ménard, E. Ezan, P. Corvol, 1996, The Journal of clinical investigation.

Plasma Soluble (Pro)Renin Receptor Is Independent of Plasma Renin, Prorenin, and Aldosterone Concentrations But Is Affected by Ethnicity

T. Hirose, A. Caumont-Prim, K. Totsune, 2014, Hypertension.

Aldosterone stimulation by angiotensin II : influence of gender, plasma renin, and familial resemblance.

S. Hunt, P. Hopkins, X. Jeunemaître, 2000, Hypertension.

Renin inhibition

M. Azizi, 2006, Current opinion in nephrology and hypertension.

Chapter 66 – Renin-Secreting Tumors and Other Renin-Secreting States

P. Plouin, L. Amar, M. Azizi, 2007 .

The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren.

J. Ménard, M. Azizi, 2007, Journal of hypertension.

Dual RAAS suppression: recent developments and implications in light of the ALTITUDE study

L. Ruilope, R. D. de Boer, R. Schmieder, 2012, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Managing cardiovascular and renal risk: the potential of direct renin inhibition

P. Sever, M. Azizi, A. Gradman, 2009, Journal of the renin-angiotensin-aldosterone system : JRAAS.

RENIN INHIBITION WITH ALISKIREN

G. Wuerzner, M. Azizi, 2008, Clinical and experimental pharmacology & physiology.

RETRACTED ARTICLE: Direct renin inhibition: clinical pharmacology

M. Azizi, 2008, Journal of molecular medicine.

Conformational changes in prorenin during renin inhibition in vitro and in vivo

J. Ménard, M. Azizi, S. Peyrard, 2006, Journal of hypertension.

Blocking the tissue renin-angiotensin system: the future cornerstone of therapy

M. Azizi, T. Unger, GG Belz, 2000, Journal of Human Hypertension.

Multiple Ascending Dose Study With the New Renin Inhibitor VTP-27999: Nephrocentric Consequences of Too Much Renin Inhibition

J. Ménard, R. Reeves, M. Azizi, 2014, Hypertension.

Renin-angiotensin system blockade: to what extent?

J. Ménard, M. Azizi, 2004, Journal of hypertension.

Blood pressure response to angiotensin II, low-density lipoprotein cholesterol and polymorphisms of the angiotensin II type 1 receptor gene in hypertensive sibling pairs

S. Hunt, P. Hopkins, X. Jeunemaître, 2001, Journal of Molecular Medicine.

Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans.

J. Schwartz, P. Boutouyrie, P. Boutouyrie, 2000, Hypertension.

Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.

J. Ménard, G. Chatellier, M. Azizi, 1999, Journal of hypertension.

Pharmacological demonstration of the additive effects of angiotensin-converting enzyme inhibition and angiotensin II antagonism in sodium depleted healthy subjects.

J. Ménard, G. Chatellier, M. Azizi, 1997, Clinical and experimental hypertension.

Additive effects of losartan and enalapril on blood pressure and plasma active renin.

J. Ménard, G. Chatellier, M. Azizi, 1997, Hypertension.

Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.

J. Ménard, G. Chatellier, M. Azizi, 1995, Circulation.

Partial human genetic deficiency in tissue kallikrein activity and renal calcium handling.

P. Houillier, X. Jeunemaître, M. Azizi, 2007, Clinical journal of the American Society of Nephrology : CJASN.

THE EUROPEAN/INTERNATIONAL FIBROMUSCULAR DYSPLASIA REGISTRY AND INITIATIVE (FEIRI)- CLINICAL PHENOTYPES AND THEIR PREDICTORS BASED ON A COHORT OF ONE THOUSAND PATIENTS.

R. Cianci, P. Salice, J. Segura, 2020, Cardiovascular research.

RHABDOMYOLYSIS AFTER ADDITION OF DIGITOXIN TO CHRONIC SIMVASTATIN AND AMIODARONE THERAPY

M. Azizi, H. Nägele, S. Hashagen, 2007, Drug metabolism and drug interactions.

Hemodynamic changes during cardiac resynchronization therapy

M. Castel, M. Azizi, H. Nägele, 2007, Clinical cardiology.

Long-term hemodynamic benefit of biventricular pacing depending on coronary sinus lead position

M. Castel, M. Azizi, H. Nägele, 2006, Herzschrittmachertherapie & Elektrophysiologie.

Experience with coronary sinus lead implantations for cardiac resynchronization therapy in 244 patients

M. Castel, M. Azizi, H. Nägele, 2006, Herzschrittmachertherapie & Elektrophysiologie.

The lactotripeptides isoleucine-proline-proline and valine-proline-proline do not inhibit the N-terminal or C-terminal angiotensin converting enzyme active sites in humans

G. Wuerzner, M. Azizi, A. Blanchard, 2009, Journal of hypertension.

Identification of Surgically Curable Primary Aldosteronism by Imaging in a Large Multiethnic International Study.

A. Oliveras, L. S. Schultze Kool, J. Widimský, 2021, The Journal of clinical endocrinology and metabolism.

High Prevalence of Multiple Arterial Bed Lesions in Patients With Fibromuscular Dysplasia: The ARCADIA Registry (Assessment of Renal and Cervical Artery Dysplasia)

P. Gosse, G. Chatellier, É. Mousseaux, 2017, Hypertension.

A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings

J. Machiels, E. Tartour, W. Fridman, 2011, Cancer Immunology, Immunotherapy.

Beyond Atherosclerosis and Fibromuscular Dysplasia: Rare Causes of Renovascular Hypertension

P. D. de Leeuw, M. Litwin, G. Wuerzner, 2021, Hypertension.

Inappropriate ICD discharge induced by electrical interference from a physio-therapeutic muscle stimulation device

M. Azizi, H. Nägele, 2006, Herzschrittmachertherapie & Elektrophysiologie.

Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension: the Survey of PatIents with treatment ResIstant hyperTension study.

S. Oparil, E. Schiffrin, N. Poulter, 2019, Journal of hypertension.

Subtyping of Primary Aldosteronism in the AVIS-2 Study: Assessment of Selectivity and Lateralization.

A. Oliveras, J. Widimský, A. Pessina, 2019, The Journal of clinical endocrinology and metabolism.

Association Between 2 Angiographic Subtypes of Renal Artery Fibromuscular Dysplasia and Clinical Characteristics

X. Jeunemaître, A. Azarine, P. Plouin, 2012, Circulation.

Genetic and dietary control of plasma tissue kallikrein secretion and urinary kinins exretion in man

M. Azizi, D. Campbell, C. Emanueli, 2008, Journal of hypertension.

The Functional c.-2G>C Variant of the Mineralocorticoid Receptor Modulates Blood Pressure, Renin, and Aldosterone Levels

F. Zitman, B. Penninx, X. Jeunemaître, 2010, Hypertension.

An abnormal apelin/vasopressin balance may contribute to water retention in patients with the syndrome of inappropriate antidiuretic hormone (SIADH) and heart failure.

G. Wuerzner, C. Llorens-Cortes, C. Gauci, 2013, The Journal of clinical endocrinology and metabolism.

Dual renin–angiotensin system blockade restores blood pressure–renin dependency in individuals with low renin concentrations

J. Ménard, A. Bissery, M. Azizi, 2003, Journal of hypertension.

Endothelial Function and Chronic Exposure to Air Pollution in Normal Male Subjects

S. Laurent, P. Boutouyrie, M. Briet, 2007, Hypertension.

Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial

A. Cremer, P. Gosse, G. Chatellier, 2017, Journal of the American Heart Association.

Haemodynamic effects of dual blockade of the renin–angiotensin system in spontaneously hypertensive rats: influence of salt

J. Ménard, M. Azizi, J. Giudicelli, 2004, Journal of hypertension.

Pilot study of combined blockade of the renin–angiotensin system in essential hypertensive patients

J. Ménard, J. Menten, M. Azizi, 2000, Journal of hypertension.

Transcriptome Analysis of Human Reninomas as an Approach to Understanding Juxtaglomerular Cell Biology

Benjamin Haibe-Kains, A. Blanchet-Cohen, P. Corvol, 2017, Hypertension.

Barriers to up-titrated antihypertensive strategies in 12 sub-Saharan African countries: the Multination Evaluation of hypertension in Sub-Saharan Africa Study

X. Jouven, J. Empana, M. Azizi, 2022, Journal of hypertension.

Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.

J. Ménard, A. Bissery, M. Azizi, 2007, Clinical journal of the American Society of Nephrology : CJASN.

2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension.

G. Lip, A. Dominiczak, G. Mancia, 2018, Journal of hypertension.

Review: Measurement of plasma renin: a critical review of methodology

J. Ménard, M. Azizi, 2010, Journal of the renin-angiotensin-aldosterone system : JRAAS.

P-glycoprotein influences urinary excretion of aldosterone in healthy individuals.

M. Loriot, C. Funck-Brentano, J. Salem, 2019, Journal of hypertension.

[Phaeochromocytoma and paraganglioma].

A. Gimenez-Roqueplo, N. Burnichon, S. Baron, 2019, La Revue de medecine interne.

Blood pressure-lowering medicines implemented in 12 African countries: the cross-sectional multination EIGHT study

X. Jouven, M. Azizi, M. Périer, 2021, BMJ Open.

Pharmacodynamic effects of dual neutral endopeptidase–angiotensin‐converting enzyme inhibition versus angiotensin‐converting enzyme inhibition in humans

J. Ménard, M. Azizi, C. Massien, 1999, Clinical pharmacology and therapeutics.

Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial.

A. Kirtane, R. Schmieder, J. Basile, 2019, Circulation.

Bipolar radiofrequency renal denervation with the Vessix catheter in patients with resistant hypertension: 2-year results from the REDUCE-HTN trial

I. Meredith, J. Ormiston, U. Hoppe, 2017, Journal of Human Hypertension.

Aldosterone receptor antagonists.

M. Azizi, 2020, Annales d'endocrinologie.

Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension

G. Chatellier, M. Azizi, T. Guyene, 1994, Journal of hypertension.

Cardiac pheochromocytomas.

M. Azizi, J. Fabiani, J. Chachques, 1992, The Annals of thoracic surgery.

Forearm ischemia decreases endothelial colony-forming cell angiogenic potential.

P. Boutouyrie, E. Bozec, M. Azizi, 2014, Cytotherapy.

European Society of Hypertension position paper on renal denervation 2021.

K. Kario, G. Mancia, M. Böhm, 2021, Journal of hypertension.

What can happen during coronary sinus lead implantation: dislocation, perforation and other catastrophes

M. Azizi, H. Nägele, S. Behrens, 2007, Herzschrittmachertherapie & Elektrophysiologie.

Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study.

A. Oliveras, L. S. Schultze Kool, J. Widimský, 2021, European journal of preventive cardiology.

Resistant Hypertension and Obstructive Sleep Apnea: Is There a Specific Indication for Endovascular Renal Denervation?

L. Amar, M. Azizi, A. Lorthioir, 2018, Hypertension.

New drug therapies interfering with the renin–angiotensin–aldosterone system for resistant hypertension

G. Bobrie, M. Azizi, M. Monge, 2013, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Progress in primary aldosteronism. Mineralocorticoid antagonist treatment for aldosterone-producing adenoma.

P. Plouin, L. Amar, M. Azizi, 2015, European journal of endocrinology.

[Vascular and renal effects of anti-angiogenic therapy].

P. Rieu, S. Oudard, O. Bouché, 2008, Nephrologie & therapeutique.

Effect of Contrasted Sodium Diets on the Pharmacokinetics and Pharmacodynamic Effects of Renin–Angiotensin System Blockers

J. Ménard, E. Ezan, C. Funck-Brentano, 2013, Hypertension.

The hemoregulatory peptide N-acetyl-ser-asp-lys-pro impairs angiotensin I-induced contractions in rat aorta.

B. Lévy, E. Ezan, M. Azizi, 1998, European journal of pharmacology.

Renal artery variations in patients with mild-to-moderate hypertension from the RADIANCE-HTN SOLO trial.

Leslie A. Coleman, A. Kirtane, Yale Wang, 2021, Cardiovascular revascularization medicine : including molecular interventions.

Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial

M. Uder, A. Cremer, P. Gosse, 2021, The Lancet.

Renal denervation for resistant hypertension – Authors' reply

P. Gosse, G. Chatellier, G. Bobrie, 2015, The Lancet.

Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake.

J. Ménard, A. Bissery, M. Azizi, 2002, Journal of the American Society of Nephrology : JASN.

Myocardial effect of converting enzyme inhibition in hypertensive and normotensive rats.

J. Michel, P. Corvol, J. Salzmann, 1988, The American journal of medicine.

Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study

P. Gosse, A. Kirtane, P. Blankestijn, 2021, Journal of Human Hypertension.

Catheter-based renal denervation for treatment of hypertension

M. Azizi, 2017, The Lancet.

Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial.

A. Kirtane, Yale Wang, P. Lurz, 2022, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Copeptin is increased in resistant hypertension

J. Ménard, G. Bobrie, M. Azizi, 2016, Journal of hypertension.

[Angioplasty for atherosclerotic renal artery stenosis: the end of the story?].

P. Plouin, L. Amar, M. Azizi, 2014, La Revue de medecine interne.

Adrenal adaptation in potassium-depleted men: role of progesterone?

M. Azizi, A. Blanchard, A. Lamaziere, 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Clinical Outcomes of 1625 Patients With Primary Aldosteronism Subtyped With Adrenal Vein Sampling.

A. Oliveras, L. S. Schultze Kool, J. Widimský, 2019, Hypertension.

12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation.

P. Gosse, A. Kirtane, R. Schmieder, 2020, JACC. Cardiovascular interventions.

Association of Smoking With Phenotype at Diagnosis and Vascular Interventions in Patients With Renal Artery Fibromuscular Dysplasia

X. Jeunemaître, A. Azarine, P. Plouin, 2013, Hypertension.

Development of enzyme-linked immunoassays for human angiotensin I converting enzyme suitable for large-scale studies

L. Tarnow, X. Jeunemaître, S. Danilov, 1996, Journal of hypertension.

Blood pressure changes after renal denervation at 10 European expert centers

J. Staessen, M. Burnier, S. Kjeldsen, 2013, Journal of Human Hypertension.

Influence of age on the outcome of percutaneous angioplasty in atheromatous renovascular disease.

X. Jeunemaître, P. Corvol, P. Plouin, 1989, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans

J. Ménard, A. Bissery, M. Azizi, 2006, Clinical pharmacology and therapeutics.

Sandwich-type enzyme immunoassay for big endothelin-I in plasma: concentrations in healthy human subjects unaffected by sex or posture.

G. Le Brun, F. Moldovan, J. Fiet, 1997, Clinical chemistry.

Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism

J. Ménard, P. Plouin, L. Amar, 2013, Journal of hypertension.

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

P. Gosse, S. Oparil, Pankaj Gupta, 2022, The Lancet.

Impaired 11-&bgr; Hydroxysteroid Dehydrogenase Type 2 Activity in Sweat Gland Ducts in Human Essential Hypertension

N. Farman, J. Fiet, M. Azizi, 2004 .

Restenosis after a first percutaneous transluminal renal angioplasty.

G. Chatellier, M. Azizi, C. Battaglia, 1993, Hypertension.

Reversible impairment of myocardial function in Hanta virus infection – direct viral effect?

M. Azizi, H. Nägele, S. Jäckle, 2006, Clinical Research in Cardiology.

A solid-phase immobilized epitope immunoassay (SPIE-IA) permitting very sensitive and specific measurement of angiotensin II in plasma.

J. Grassi, C. Créminon, M. Azizi, 1999, Journal of immunological methods.

A role for succinate dehydrogenase genes in low chemoresponsiveness to hypoxia?

J. Elghozi, J. Richalet, A. Vénisse, 2009, Clinical Autonomic Research.

Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension

G. Chatellier, K. Kario, K. Shimada, 2015, Blood pressure.

Cause of renal infarction: a retrospective analysis of 186 consecutive cases

A. Azarine, G. Bobrie, P. Plouin, 2017, Journal of hypertension.

Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series.

S. Oudard, L. Fournier, F. Scotté, 2009, European urology.

Effect of vasodilatators on the structure of the aorta in normotensive ageing rats.

J. Ménard, J. Michel, B. Lévy, 1987, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI)-clinical phenotypes and their predictors based on a cohort of 1000 patients

L. Mazzolai, W. Spiering, D. Gordin, 2020 .

Plasma renin and aldosterone concentrations related to endovascular ultrasound renal denervation in the RADIANCE-HTN SOLO trial

P. Gosse, R. Schmieder, A. Kirtane, 2021, Journal of hypertension.

Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial

Neil Chapman, Manish Saxena, Jai Radhakrishnan, 2018, The Lancet.

ESH-ENDORSED EUROPEAN/INTERNATIONAL FIBROMUSCULAR DYSPLASIA REGISTRY: RESULTS OF THE FIRST 609 PATIENTS

A. Kroon, L. Toubiana, I. Tikkanen, 2018, Journal of Hypertension.

Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans.

A. Bissery, S. Laurent, P. Boutouyrie, 2005, The Journal of clinical investigation.

Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension

J. Staessen, S. Kjeldsen, M. Azizi, 2016, Hypertension.

[Natural history of renal artery stenosis].

M. Azizi, 1996, La Revue du praticien.

RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis.

P Corvol, A Yiotakis, V Dive, 2001, The Journal of pharmacology and experimental therapeutics.

Human in vivo study of the renin–angiotensin–aldosterone system and the sympathetic activity after 8 weeks daily intake of fermented milk

A. Linneberg, H. Ibsen, M. Azizi, 2010, Clinical physiology and functional imaging.

HPLC–DAD Analysis of Hydrochlorothiazide and Irbesartan in Hypertensive Patients on Fixed-Dose Combination Therapy

P. Beaune, G. Bobrie, M. Azizi, 2011 .

Home blood pressure measurement and digital health: communication technologies create a new context

G. Parati, N. Postel-Vinay, G. Bobrie, 2018, Journal of hypertension.

Design Considerations for Clinical Trials of Autonomic Modulation Therapies Targeting Hypertension and Heart Failure

I. Piña, R. Kieval, G. Bakris, 2015, Hypertension.

Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin–angiotensin blockade for left ventricular mass regression in patients with resistant hypertension

J. Ménard, G. Chatellier, G. Bobrie, 2014, Journal of hypertension.

Sequential nephron blockade versus sequential renin–angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study

J. Ménard, G. Chatellier, S. Laurent, 2012, Journal of hypertension.

PHACTR1 Is a Genetic Susceptibility Locus for Fibromuscular Dysplasia Supporting Its Complex Genetic Pattern of Inheritance

P. Ellinor, X. Jouven, I. Kullo, 2016, PLoS genetics.

First-in-man randomized clinical trial of renal denervation for atrial arrhythmia raises concern.

J. Staessen, L. Thijs, S. Kjeldsen, 2013, Journal of the American College of Cardiology.

Aldosterone synthase inhibition in humans.

J. Ménard, L. Amar, M. Azizi, 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Targeting the aldosterone pathway in cardiovascular disease

F. Jaisser, P. Rossignol, J. Bauersachs, 2012, Fundamental & clinical pharmacology.

Criteria for diagnosing primary aldosteronism on the basis of liquid chromatography–tandem mass spectrometry determinations of plasma aldosterone concentration

P. Houillier, S. Baron, L. Amar, 2018, Journal of hypertension.

Renal Outcome and New-Onset Renal and Extrarenal Dissections in Patients With Nontrauma Renal Artery Dissection Associated With Renal Infarction

É. Mousseaux, A. Azarine, G. Bobrie, 2021, Hypertension.

Acute and chronic effects of acupuncture on radial artery: A randomized double blind study in migraine

P. Boutouyrie, B. Laloux, M. Azizi, 2010 .

Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19

Ji-Guang Wang, M. Burnier, T. Riemer, 2020, Cardiovascular research.

Device-based therapies for arterial hypertension

A. Kirtane, M. Böhm, F. Mahfoud, 2020, Nature Reviews Cardiology.

A6 - Short term effects of octreotide on blood pressure and plasma catecholamines and neuropeptidey levels in patients with pheochromocytoma: A placebo-controlled trial

G. Chatellier, J. Bertherat, P. Plouin, 1995 .

Short‐term effects of octreotide on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with phaeochromocytoma: a placebo‐controlled trial

J. Bertherat, P. Plouin, M. Azizi, 1995, Clinical endocrinology.

[Presentations and management of adrenal hypertension].

P. Plouin, L. Amar, M. Azizi, 2014, Presse medicale.

Carotid stiffness change over the cardiac cycle by ultrafast ultrasound imaging in healthy volunteers and vascular Ehlers–Danlos syndrome

Mathieu Couade, Mathieu Pernot, Emmanuel Messas, 2015, Journal of hypertension.

Tissue kallikrein gene polymorphisms induce no change in endothelium-dependent or independent vasodilation in hypertensive and normotensive subjects

X. Jeunemaître, L. Ghiadoni, S. Favilla, 2006, Journal of hypertension.

Eligibility for Renal Denervation: Anatomical Classification and Results in Essential Resistant Hypertension

M. Yamaguchi, G. Bobrie, P. Plouin, 2015, CardioVascular and Interventional Radiology.

Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design.

G. Chatellier, G. Parati, G. Grassi, 2015, European heart journal.

Renin Inhibitors and Cardiovascular and Renal Protection: An Endless Quest?

J. Ménard, M. Azizi, 2013, Cardiovascular Drugs and Therapy.

Rationale for combining blockers of the renin-angiotensin system.

G. Wuerzner, M. Azizi, 2007, Seminars in nephrology.

Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists

J. Ménard, M. Azizi, 2004, Circulation.

Effects of chronic inhibition of converting enzyme on mechanical and structural properties of arteries in rat renovascular hypertension.

M. Safar, J. Michel, B. Lévy, 1988, Circulation research.

Clinic Versus Ambulatory Blood Pressure in Resistant Hypertension: Impact of Antihypertensive Medication Nonadherence: A Post Hoc Analysis the DENERHTN Study.

A. Cremer, P. Gosse, P. Rossignol, 2019, Hypertension.

Combined blockade of the renin-angiotensin system Key-words (Index medicus): Renin. Hypertension. Diabetes Mellitus. Cardio- vascular Diseases

M. Azizi, 2014 .

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.

Joël Ménard, J. Ménard, A. Bissery, 2004, Journal of the American Society of Nephrology : JASN.

Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats.

J. Ménard, M. Azizi, D. Campbell, 1997, Circulation.

Drug adherence in hypertension: from methodological issues to cardiovascular outcomes.

S. Laurent, P. Boutouyrie, M. Azizi, 2017, Journal of hypertension.

Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies

G. Chatellier, G. Parati, G. Grassi, 2020, European heart journal.

Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

G. Parati, T. Lüscher, C. Tsioufis, 2023, European heart journal.

Detecting Nonadherence to Antihypertensive Treatment: Any Time, Anywhere?

S. Laurent, M. Azizi, V. Jullien, 2017, Hypertension.

Adherence to Antihypertensive Treatment and the Blood Pressure–Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial

P. Gosse, G. Chatellier, F. Zannad, 2016, Circulation.

7B.06: ROUTINE URINARY DETECTION OF ANTIHYPERTENSIVE DRUGS FOR ESTIMATION OF ADHERENCE TO TREATMENT A CROSS SECTIONAL STUDY

S. Laurent, P. Boutouyrie, M. Azizi, 2015, Journal of Hypertension.

Routine urinary detection of antihypertensive drugs for systematic evaluation of adherence to treatment in hypertensive patients

S. Laurent, P. Boutouyrie, M. Azizi, 2017, Journal of hypertension.

SPARTE Study: Normalization of Arterial Stiffness and Cardiovascular Events in Patients With Hypertension at Medium to Very High Risk

P. Gosse, G. Chatellier, S. Laurent, 2021, Hypertension.

Catheter-based radiofrequency renal-nerve ablation in patients with resistant hypertension.

G. Bobrie, P. Plouin, M. Azizi, 2012, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

The corona-virus disease 2019 pandemic compromised routine care for hypertension: a survey conducted among excellence centers of the European Society of Hypertension

N. Chapman, C. Giannattasio, M. Muiesan, 2021, Journal of hypertension.

How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an example

I. Durand-zaleski, M. Azizi, M. Darlington, 2018, Blood pressure.

Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.

Roland E Schmieder, Andrzej Januszewicz, R. Schmieder, 2007, American journal of hypertension.

Renin inhibition with aliskiren: where are we now, and where are we going?

N. Hollenberg, M. Azizi, R. Webb, 2006, Journal of hypertension.

Inappropriate shock during left ventricular threshold measurement in a patient with coexisting ICD and a biventricular pacemaker

M. Azizi, H. Nägele, 2007, Herzschrittmachertherapie & Elektrophysiologie.

Thromboangiitis obliterans and endothelial function

S. Laurent, P. Boutouyrie, J. Fiessinger, 2010, European journal of clinical investigation.

Long-term follow–up of a malpositioned ventricular pacing lead via the aortic valve

M. Azizi, H. Nägele, S. Hashagen, 2006, Clinical Research in Cardiology.

Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial.

Raghava R. Gollapudi, A. Cremer, S. Padmanabhan, 2023, JAMA.

Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials

P. Gosse, J. Basile, A. Kirtane, 2023, JAMA cardiology.

What We Know and Don't Know About Renal Denervation to Lower Blood Pressure.

A. Kirtane, M. Azizi, K. Chau, 2022, JAMA cardiology.

Protocol of the SPARTE Study: A Strategy for Preventing Cardiovascular and Renal Events based on ARTErial Stiffness

P. Gosse, G. Chatellier, D. Calvet, 2020, Artery Research.

Longitudinal strain of systemic right ventricle correlates with exercise capacity in adult with transposition of the great arteries after atrial switch.

G. Chatellier, É. Mousseaux, L. Iserin, 2016, International journal of cardiology.

Randomised, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Study of QGC001, a Centrally Acting Aminopeptidase A Inhibitor Prodrug

B. Roques, C. Llorens-Cortes, M. Azizi, 2014, Clinical Pharmacokinetics.

G. Parati, T. Lüscher, C. Tsioufis, 2023, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Feasibility of Imaging-Guided Adrenalectomy in Young Patients With Primary Aldosteronism

A. Oliveras, J. Widimský, M. Quinkler, 2021, Hypertension.

Hypertension management in patients with cardiovascular comorbidities.

Deepak L. Bhatt, K. Kario, G. Parati, 2022, European heart journal.

Rare loss-of-function mutations of PTGIR are enriched in fibromuscular dysplasia

N. Samani, S. Hazen, É. Mousseaux, 2020, Cardiovascular research.

Method of mean value calculation as an additional source of variability in ambulatory blood pressure measurement.

G. Bobrie, M. Azizi, S. Peyrard, 2010, American journal of hypertension.

Angiotensin II Activates the RhoA Exchange Factor Arhgef1 in Humans

X. Jeunemaître, P. Pacaud, M. Azizi, 2015, Hypertension.

Cardiometabolic Disorders and the Risk of Critical COVID-19 as Compared to Influenza Pneumonia

G. Chatellier, S. Czernichow, D. Lebeaux, 2021, Journal of Clinical Medicine.

Proteinuria in renal artery occlusion is related to active renin concentration and contralateral kidney size

G. Chatellier, P. Rossignol, P. Plouin, 2002, Journal of hypertension.

Impaired 11-beta hydroxysteroid dehydrogenase type 2 activity in sweat gland ducts in human essential hypertension.

N. Farman, J. Fiet, M. Azizi, 2004, Hypertension.

Differential association between inflammatory cytokines and multiorgan dysfunction in COVID-19 patients with obesity

É. Mousseaux, E. Tartour, S. Czernichow, 2021, PloS one.

Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation: A Post Hoc Analysis of the RADIANCE-HTN SOLO Study.

A. Cremer, P. Gosse, K. Kario, 2020, Hypertension.

Hypokalemia, aldosteronism, and renal cysts.

G. Chatellier, W. Young, K. Offord, 1990, The New England journal of medicine.

Arterial effects of angiotensin converting enzyme inhibition in renovascular and spontaneously hypertensive rats.

M. Safar, J. Michel, B. Lévy, 1988, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH).

A. Dominiczak, G. Parati, G. Grassi, 2023, Journal of hypertension.

A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension.

C. Llorens-Cortes, L. Amar, M. Azizi, 2019, Journal of hypertension.

Do we need angiotensin II antagonists to treat hypertensive patients?

J. Ménard, G. Chatellier, M. Azizi, 1997, Journal of human hypertension.

Impaired atrioventricular transport in patients with transposition of the great arteries palliated by atrial switch and preserved systolic right ventricular function: A magnetic resonance imaging study

G. Chatellier, É. Mousseaux, N. Kachenoura, 2017, Congenital heart disease.

LB01.11: PREVALENCE OF SECONDARY HYPERTENSION IN YOUNG HYPERTENSIVE ADULTS

N. Postel-Vinay, G. Bobrie, L. Amar, 2015, Journal of hypertension.

Will SPYRAL HTN-OFF MED change my practice? SPYRAL HTN-OFF MED: a prospective, randomised, sham-controlled trial on renal denervation in the absence of antihypertensive medications.

C. Tsioufis, L. Mauri, W. Wijns, 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

A STABLE AMIDE ANALOG OF THE NATURAL HAEMATOLOGICAL TETRAPEPTIDE N-ACETYL-SERYL-ASPARTYL-LYSYL-PROLINE AS A NEW INDEX OF GLOMERULAR FILTRATION RATE: A PRE-CLINICAL STUDY

E. Ezan, M. Azizi, A. Herbet, 2004 .

Genetic association studies of fibromuscular dysplasia identify new risk loci and shared genetic basis with more common vascular diseases

Lu Liu, P. Amouyel, M. Zawistowski, 2020, medRxiv.

Will SPYRAL HTN-ON MED change my practice? SPYRAL HTN-ON MED: a prospective, randomised, sham-controlled trial on renal denervation in the presence of antihypertensive medications.

T. Lüscher, D. Kandzari, W. Wijns, 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial

A. Cremer, P. Gosse, G. Chatellier, 2017, Journal of the American Heart Association.

Abstract P3-15-06: Results of the MARS study on the management of antiangiogenics’ renovascular safety in breast cancer

O. Mir, I. Ray-Coquard, F. Goldwasser, 2013 .

Results of the MARS study on the management of antiangiogenics’ renovascular safety in ovarian cancer.

O. Mir, I. Ray-Coquard, F. Goldwasser, 2013 .

Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism

J. Ménard, P. Plouin, L. Amar, 2010, HYPERTENSION.

Targeting the aldosterone pathway in cardiovascular disease

F. Jaisser, P. Rossignol, J. Bauersachs, 2012, Fundamental & clinical pharmacology.

Adherence to Antihypertensive Treatment and the Blood Pressure–Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial

P. Gosse, G. Chatellier, F. Zannad, 2016, Circulation.